Bio-Works confirms new order from Nemysis Limited worth 2.1 million SEK
Bio-Works Technologies AB has confirmed that they have received a new order from Nemysis Limited, an Irish based company developing enzymatic solutions for gluten intolerance. The order, worth €203K (2.1 million SEK) is confirmed for delivery in the fourth quarter of this year.
“We are proud that Nemysis Limited has chosen Bio-Works to supply purification solutions for their production. Nemysis and Bio-Works are both companies which are working to develop and commercialize novel technologies,” said Jonathan Royce, CEO of Bio-Works Technologies.”As such, it is exciting that the Bio-Works solution which Nemysis has chosen is a product which we launched last year.”
Nemysis Ltd, a healthcare and pharmaceutical company, is focused on nutritional and pharmaceutical solutions that can protect against some of the negative consequences of nutrient deficiency, nutrient intolerances and sensitivities, paying particular attention to the need to safeguard the human microbiome. Nemysis’s novel E40 endopeptidase is gastric, trypsin and chymotrypsin resistant. It has been shown to destroy all the immuno-stimulatory epitopes of gluten, quenching the exacerbated inflammatory response of primed, gluten-sensitive and hyper-responsive human T cells. It is, therefore, suitable for the enzymatic management of gluten intolerance and sensitivity.Nemysis’s novel nanoparticulate iron is the first natural ferritin mimic, which can correct human iron deficiency and anemia, without negatively impacting the gut microbiome. Safety and efficacy have been demonstrated in controlled-repeat-dose clinical trials.
Bio-Works designs, develops, manufactures and supplies innovative leading-edge agarose products for chromatographic separation of proteins, peptides and other biomolecules. Bio-Works’ agarose based high performance products are used for purification in the life science research phases as well as the commercial production of biopharmaceuticals and diagnostic products in large scale. The products are sold globally with our own organization and via distributors. The Bio-Works’ headquarter with R&D and manufacturing is located in Uppsala Business Park in Uppsala, Sweden and the company processes and a Quality Management System follow the standards of ISO 9001:2015.
Bio-Works' share is listed on Nasdaq First North. FNCA Sweden AB, +46 (0) 8-528 00 399, info@fnca.se, is appointed Certified Advisor.
This is an English translation of a press release issued in Swedish on September 28, 2021. This translation is provided for convenience.
For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Jonathan Royce, CEO, e-mail: jonathan.royce@bio-works.com, phone: +46 70 1434143.
